Company / Cost of Revenue
NEKTAR THERAPEUTICS Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
-
FY2025
5-year range
$0 / $33.8M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#83 of 85
Health Care
What the data says
Improved from $25M to $0 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 85
▼
Key checks
Key Insights
- In FY2025, cost of revenue decreased 100.0% year-over-year.
- Peak cost of revenue was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $33.8M | +35.6% |
| FY2023 | $24.9M | +15.1% |
| FY2022 | $21.6M | -13.1% |
| FY2021 | $24.9M | +2.0% |
| FY2020 | $24.4M | -20.1% |
| FY2019 | $30.5M | +1.1% |
| FY2018 | $30.2M | -1.1% |
| FY2017 | $30.5M | +7.1% |
| FY2016 | $28.5M | -16.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026